Senolytic therapy for diabetic macular edema (DME) refractory to anti-VEGF treatment appears safe, and preliminary data suggest a therapeutic effect on visual acuity and macular thickness.
References
Teo, Z. L. et al. Ophthalmology 128, 1580–1591 (2021).
Ciulla, T. A., Pollack, J. S. & Williams, D. F. Br. J. Ophthalmol. 105, 216–221 (2021).
Wykoff, C. C. et al. Lancet 399, 741–755 (2022).
Crespo-Garcia, S. et al. Nat. Med. https://doi.org/10.1038/s41591-024-02802-4 (2024).
Antonetti, D. A., Silva, P. S. & Stitt, A. W. Nat. Rev. Endocrinol. 17, 195–206 (2021).
Oshitari, T. Int. J. Mol. Sci. 24, 12919 (2023).
Gorgoulis, V. et al. Cell 179, 813–827 (2019).
Liu, H. et al. JCI Insight 8, e168945 (2023).
El-Nimri, N. W. et al. Sci. Rep. 10, 21752 (2020).
Wong, F., Omori, S., Donghia, N. M., Zheng, E. J. & Collins, J. J. Nat. Aging 3, 734–750 (2023).
Cordeiro, M. F. et al. Prog. Retin. Eye Res. 86, 100976 (2022).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Murakami, T., Gardner, T.W. Rejuvenation of diabetic macular edema with senolytic therapy. Nat Med 30, 346–347 (2024). https://doi.org/10.1038/s41591-024-02804-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-02804-2
- Springer Nature America, Inc.